SOUTH SAN FRANCISCO, Calif. — March 2, 2026 — Leads & Copy — Tenaya Therapeutics, Inc. (NASDAQ: TNYA) announced its management will participate in the Leerink Partners Global Healthcare Conference, scheduled for March 9-11, 2026, in Miami, Florida.
Faraz Ali, Tenaya’s Chief Executive Officer, is slated to participate in a fireside chat on Monday, March 9, 2026, at 1:00 pm ET.
The live webcast of the fireside chat will be accessible via the Investors section of Tenaya’s website. An archived replay of the webcast will be available on the Tenaya website for about 30 days after the conference.
Tenaya Therapeutics is focused on discovering, developing, and delivering potentially curative therapies addressing the underlying causes of heart disease. Their pipeline features clinical-stage candidates such as TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
Tenaya utilizes integrated internal capabilities, including target validation, capsid engineering, and manufacturing, to develop medicines based on genetic insights. These include TN-301, a clinical-stage small molecule HDAC6 inhibitor for potential heart failure treatment, and several early-stage preclinical programs targeting rare genetic disorders and prevalent heart conditions.
Source: Tenaya Therapeutics
